Transaction #23820 · Form 4 · 0001104659-25-123597
Kyverna Therapeutics, Inc. · Purchase · Common Stock
Kyverna Therapeutics, Inc. · Transacted December 18, 2025 · Filed December 22, 2025
What does this filing report?
An SEC Form 4 filing for Kyverna Therapeutics, Inc. records a purchase involving Common Stock on December 18, 2025. The reported quantity was 133,333. The filing date is December 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Kyverna Therapeutics, Inc.
- Company CIK
- 0001994702
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 133,333
- Reported price
- 7.5
- Reference value
- 999,997.5
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 869,317
- Ownership description
- See Footnote
- SEC acceptance time
- Dec 22, 2025, 11:43 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- SEIDENBERG BETH C ↗
Director
CIK 0001184592
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The Reporting Person is the managing director of Westlake Opportunity GP I and has sole voting and dispositive control over Westlake Opportunity GP I, and disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of the Reporting Person's pecuniary interest therein, if any.
- F2
- Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The Reporting Person is the managing director of Westlake GP I and has sole voting and dispositive control over Westlake GP I, and disclaims beneficial ownership of the shares held by Westlake I except to the extent of the Reporting Person's pecuniary interest therein, if any.
- F3
- Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 29, 2026, and (ii) immediately prior to the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.